Understand the source comparison
Mazdutide Stack Comparison: Receptor Pathways and Side Effect Profiles
Mazdutide + CJC-1295/Ipamorelin GLP-1/GIP + GHSR None (6.5d vs 30min pulses) Low. No gastric overlap High. GLP-1 suppresses appetite, GH preserves lean mass during deficit Proven pairing in body recomposition research; GH component counteracts muscle loss Mazd
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mazdutide + CJC-1295/Ipamorelin
- GLP-1/GIP + GHSR
- None (6.5d vs 30min pulses)
- Low. No gastric overlap
- High. GLP-1 suppresses appetite, GH preserves lean mass during deficit
- Proven pairing in body recomposition research; GH component counteracts muscle loss
- Mazdutide + Semaglutide
- Both GLP-1/GIP agonists
- Total (both 5–7d half-lives)
- Severe. Compounded nausea, vomiting
- None. Receptor saturation ceiling reached
- Redundant and poorly tolerated; no additional benefit vs dose escalation of one agent
- Mazdutide + Dihexa
- GLP-1/GIP + HGF receptor
- None (6.5d vs 4h)
- None. Entirely separate systems
- Cognitive enhancement without metabolic interference
- Clean stack for research addressing metabolic + neurodegenerative models
- Mazdutide + Thymalin
- GLP-1/GIP + thymic immune modulation
- None (6.5d vs 10d)
- None. No GI mechanism
- Longevity-focused: metabolic health + immune restoration
- Common in aging research protocols; pathways don't interact
- Mazdutide + Tesofensine
- GLP-1/GIP + monoamine reuptake inhibition
- Moderate (6.5d vs 8d)
- Moderate. Both delay gastric emptying
- High. Dual appetite suppression through different mechanisms
- Effective but requires GI tolerance monitoring; CNS + incretin synergy
- Mazdutide + Cerebrolysin
- GLP-1/GIP + neurotrophic factor modulation
- None (6.5d vs 10h)
- None. Separate organ systems
- Neuroprotection without metabolic pathway conflict
- Used in metabolic syndrome + cognitive impairment research